PTEN protein expression has role in predicting disease-free-interval in endometrioid endometrial carcinoma

Mohamad Nasir Shafiee; Wei Keith Lim; Cheryl Poh Shwen Shi; Ira Adila Mohamed Yasin; Aina Fatini Azemi; Muhammad Luqman Zakaria; Abdul Muzhill Hannaan Abdul Hafizz; Muaatamarulain Mustangin; Nirmala Chandralega Kampan; Nor Haslinda Abd Aziz; Reena Rahayu Md Zain

doi:10.1515/hmbci-2021-0017

Artikel

PTEN protein expression has role in predicting disease-free-interval in endometrioid endometrial carcinoma

Mohamad Nasir Shafiee , Wei Keith Lim , Cheryl Poh Shwen Shi , Ira Adila Mohamed Yasin , Aina Fatini Azemi , Muhammad Luqman Zakaria , Abdul Muzhill Hannaan Abdul Hafizz , Muaatamarulain Mustangin , Nirmala Chandralega Kampan , Nor Haslinda Abd Aziz und Reena Rahayu Md Zain

Veröffentlicht/Copyright: 9. August 2021

Veröffentlicht von

Veröffentlichen auch Sie bei De Gruyter Brill

Manuskript einreichen Informationen für Autor*innen Erkunden Sie dieses Fachgebiet

Aus der Zeitschrift Hormone Molecular Biology and Clinical Investigation Band 42 Heft 4

Abstract

Objectives

To determine the significance of tumour PTEN protein expression in endometrioid endometrial carcinoma (EEC) and it is correlation with tumour characteristics.

Methods

A total of 30 eligible archived paraffin-embedded tissue blocks from 61 EEC cases (January 2015–December 2017) were retrieved from the Histopathology Laboratory in Universiti Kebangsaan Malaysia Medical Centre (UKMMC) following institutional ethic approval. For PTEN protein detection, immunohistochemistry (IHC) staining was performed and the data was correlated with clinicopathologic parameters.

Results

Fourteen samples (46.7%) showed positive PTEN protein expression, while 16 (53.3%) were negative. The mean age was 62.00 ± 9.51 years old, while the mean Body Mass Index (BMI) was 27.28 ± 7.16 kg/m². There was no significant difference between age (p=0.27, 95% CI: −10.98 to 3.21) and BMI (p=0.67, 95% CI: −4.30 to 6.58) with PTEN protein expression. There were significant correlation between PTEN protein expression with myometrial invasion (p=0.010), but not with lymphovascular space invasion (p=0.743), grade (p=0.532), stage (p=0.733) and CA-125 level (p=0.47). The higher stage correlates with the presence of LVSI (p=0.002). PTEN positive associated with longer disease-free-interval (p=0.025), but not improving the overall survival (p=0.38)

Conclusions

Positive PTEN protein expression correlates with less myometrial invasion.

Keywords: disease-free-interval; endometrial carcinoma; endometrioid; PTEN

Corresponding author: Mohamad Nasir Shafiee, MD(UKM), MOG (UKM), MRCOG (UK), PhD (Nottingham, UK), Department of Obstetrics and Gynaecology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, 56000 Cheras, Kuala Lumpur, Malaysia, Phone: +60192787897, Fax: +60391455949, E-mail: nasirshafiee@ukm.edu.my

Funding source: Faculty of Medicine, Universiti Kebangsaan Malaysia

Award Identifier / Grant number: FF-2019-230

Acknowledgement

The present study was financially supported by a grant from the Faculty of Medicine, Universiti Kebangsaan Malaysia (code project: FF-2019-230) for the undergraduate Special Research Module. The authors would like to thank the Faculty of Medicine, Universiti Kebangsaan Malaysia for supporting the research.

Research funding: This study was financially supported by a grant from the Faculty of Medicine, Universiti Kebangsaan Malaysia (code project: FF-2019-230) for undergraduate Special Research Module.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Disclosure statement: This study was approved by the Research Ethics Committee, Faculty of Medicine, Universiti Kebangsaan Malaysia (FF-2019-230). All authors declare no conflict of interest.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: The local Institutional Review Board deemed the study exempt from review. The registration code is FF-2019-230.

References

1. Wan-Nor-Asyikeen, WA, Jalil, NAC, Zain, AAM, Siti-Azrin, A, Che Jalil, N, Othman, N, et al.. Endometrial cancer in hospital Universiti Sains Malaysia. Asian Pac J Cancer Prev APJCP 2016;17:2867–70.Suche in Google Scholar

2. Zainal Ariffin, O, Nor Saleha, I. National cancer registry report 2007. Malaysia: Ministry of Health; 2011.Suche in Google Scholar

3. Setiawan, VW, Yang, HP, Pike, MC, McCann, SE, Yu, H, Xiang, Y-B, et al.. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 2013;31:2607. https://doi.org/10.1200/jco.2012.48.2596.Suche in Google Scholar PubMed PubMed Central

4. Lax, SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004;444:213–23. https://doi.org/10.1007/s00428-003-0947-3.Suche in Google Scholar PubMed

5. Rewcastle, E, Varhaugvik, AE, Gudlaugsson, E, Steinbakk, A, Skaland, I, van Diermen, B, et al.. Assessing the prognostic value of PAX2 and PTEN in endometrial carcinogenesis. Endocr Relat Canc 2018;25:981–91. https://doi.org/10.1530/erc-18-0106.Suche in Google Scholar PubMed

6. Ellenson, L. Uterine cancer: American cancer society Atlas of clinical oncology. Br J Canc 2005;92:415. https://doi.org/10.1038/sj.bjc.6602352.Suche in Google Scholar

7. Lupini, L, Scutiero, G, Iannone, P, Martinello, R, Bassi, C, Ravaioli, N, et al.. Molecular biomarkers predicting early development of endometrial carcinoma: a pilot study. Eur J Canc Care 2019;28:e13137. https://doi.org/10.1111/ecc.13137.Suche in Google Scholar PubMed

8. Garg, K, Broaddus, RR, Soslow, RA, Urbauer, DL, Levine, DA, Djordjevic, B. Pathological scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. Int J Gynecol Pathol 2012;31:48. https://doi.org/10.1097/pgp.0b013e3182230d00.Suche in Google Scholar PubMed PubMed Central

9. Sangale, Z, Prass, C, Carlson, A, Tikishvili, E, DeGrado, J, Lanchbury, J, et al.. A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl Immunohistochem Mol Morphol 2011;19:173–83. https://doi.org/10.1097/pai.0b013e3181f1da13.Suche in Google Scholar PubMed

10. Li, Y, Bian, Y, Wang, K, Wan, X-P. POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction. BMC Med Genet 2019;20:202. https://doi.org/10.1186/s12881-019-0936-2.Suche in Google Scholar PubMed PubMed Central

11. López-Reig, R, Fernández-Serra, A, Romero, I, Zorrero, C, Illueca, C, García-Casado, Z, et al.. Prognostic classification of endometrial cancer using a molecular approach based on a twelve-gene NGS panel. Sci Rep 2019;9:18093. https://doi.org/10.1038/s41598-019-54624-x.Suche in Google Scholar PubMed PubMed Central

12. Raffone, A, Travaglino, A, Saccone, G, Viggiani, M, Giampaolino, P, Insabato, L, et al.. PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis. Arch Gynecol Obstet 2019;299:1511–24. https://doi.org/10.1007/s00404-019-05123-x.Suche in Google Scholar PubMed

13. Travaglino, A, Raffone, A, Saccone, G, Insabato, L, Mollo, A, De Placido, G, et al.. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2018;231:104–10. https://doi.org/10.1016/j.ejogrb.2018.10.025.Suche in Google Scholar

14. Raffone, A, Travaglino, A, Saccone, G, Campanino, MR, Mollo, A, De Placido, G, et al.. Loss of PTEN expression as diagnostic marker of endometrial precancer: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2019;98:275–86. https://doi.org/10.1111/aogs.13513.Suche in Google Scholar

15. Travaglino, A, Raffone, A, Saccone, G, Mascolo, M, Pignatiello, S, Mollo, A, et al.. PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer? APMIS (Acta Pathol Microbiol Immunol Scand) 2019;127:161–9. https://doi.org/10.1111/apm.12938.Suche in Google Scholar

16. Jia, P, Zhao, Z. Impacts of somatic mutations on gene expression: an association perspective. Briefings Bioinf 2017;18:413–25. https://doi.org/10.1093/bib/bbw037.Suche in Google Scholar

17. Anderson, B, Connor, JP, Andrews, JI, Davis, CS, Buller, RE, Sorosky, JI, et al.. Obesity and prognosis in endometrial cancer. Am J Obstet Gynecol 1996;174:1171–9. https://doi.org/10.1016/s0002-9378(96)70659-2.Suche in Google Scholar

18. Courneya, KS, Karvinen, KH, Campbell, KL, Pearcey, RG, Dundas, G, Capstick, V, et al.. Associations among exercise, body weight, and quality of life in a population-based sample of endometrial cancer survivors. Gynecol Oncol 2005;97:422–30. https://doi.org/10.1016/j.ygyno.2005.01.007.Suche in Google Scholar PubMed

19. Shafiee, MN, Seedhouse, C, Mongan, N, Chapman, C, Deen, S, Abu, J, et al.. Up-regulation of genes involved in the insulin signalling pathway (IGF1, PTEN and IGFBP1) in the endometrium may link polycystic ovarian syndrome and endometrial cancer. Mol Cell Endocrinol 2016;424:94–101. https://doi.org/10.1016/j.mce.2016.01.019.Suche in Google Scholar PubMed

20. Westin, SN, Ju, Z, Broaddus, RR, Krakstad, C, Li, J, Pal, N, et al.. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol 2015;9:1694–703. https://doi.org/10.1016/j.molonc.2015.04.014.Suche in Google Scholar PubMed PubMed Central

21. Hatakeyama, K, Ohshima, K, Nagashima, T, Ohnami, S, Ohnami, S, Serizawa, M, et al.. Molecular profiling and sequential somatic mutation shift in hypermutator tumours harbouring POLE mutations. Sci Rep 2018;8:8700. https://doi.org/10.1038/s41598-018-26967-4.Suche in Google Scholar PubMed PubMed Central

22. Raffone, A, Travaglino, A, Gabrielli, O, Micheli, M, Zuccalà, V, Bitonti, G, et al.. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer. Arch Gynecol Obstet 2021;303:1393–400. https://doi.org/10.1007/s00404-021-06028-4.Suche in Google Scholar PubMed PubMed Central

23. Stålberg, K, Bjurberg, M, Borgfeldt, C, Carlson, J, Dahm-Kähler, P, Flöter-Rådestad, A, et al.. Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer–a Swedish Gynecologic Cancer Group (SweGCG) study. Acta Oncol 2019;58:1628–33. https://doi.org/10.1080/0284186x.2019.1643036.Suche in Google Scholar

24. Karnezis, AN, Leung, S, Magrill, J, McConechy, MK, Yang, W, Chow, C, et al.. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. J Pathol: Clin Res 2017;3:279–93. https://doi.org/10.1002/cjp2.82.Suche in Google Scholar PubMed PubMed Central

25. Sal, V, Demirkiran, F, Erenel, H, Tokgozoglu, N, Kahramanoglu, I, Bese, T, et al.. Expression of PTEN and β-catenin and their relationship with clinicopathological and prognostic factors in endometrioid type endometrial cancer. Int J Gynecol Canc 2016;26:512–20. https://doi.org/10.1097/igc.0000000000000626.Suche in Google Scholar

26. Choi, BH, Xie, S, Dai, W. PTEN is a negative regulator of mitotic checkpoint complex during the cell cycle. Exp Hematol Oncol 2017;6:1–7. https://doi.org/10.1186/s40164-017-0079-0.Suche in Google Scholar PubMed PubMed Central

27. George, S, Miao, D, Demetri, GD, Adeegbe, D, Rodig, SJ, Shukla, S, et al.. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity 2017;46:197–204. https://doi.org/10.1016/j.immuni.2017.02.001.Suche in Google Scholar PubMed PubMed Central

28. Bian, X, Gao, J, Luo, F, Rui, C, Zheng, T, Wang, D, et al.. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 2018;37:341–51. https://doi.org/10.1038/onc.2017.326.Suche in Google Scholar PubMed PubMed Central

29. Joshi, A, Ellenson, LH. Adenovirus mediated homozygous endometrial epithelial Pten deletion results in aggressive endometrial carcinoma. Exp Cell Res 2011;317:1580–9. https://doi.org/10.1016/j.yexcr.2011.03.006.Suche in Google Scholar PubMed PubMed Central

30. Soslow, RA, Tornos, C, Park, KJ, Malpica, A, Matias-Guiu, X, Oliva, E, et al.. Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the International society of gynecological pathologists. Int J Gynecol Pathol 2019;38. https://doi.org/10.1097/PGP.0000000000000518.Suche in Google Scholar PubMed PubMed Central

31. Huang, HN, Lin, MC, Tseng, LH, Chiang, YC, Lin, LI, Lin, YF, et al.. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID 1A expression. Histopathology 2015;66:517–28. https://doi.org/10.1111/his.12543.Suche in Google Scholar PubMed

32. Djordjevic, B, Hennessy, BT, Li, J, Barkoh, BA, Luthra, R, Mills, GB, et al.. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol 2012;25:699–708. https://doi.org/10.1038/modpathol.2011.208.Suche in Google Scholar PubMed PubMed Central

Received: 2021-03-03

Accepted: 2021-07-11

Published Online: 2021-08-09

Sie haben derzeit keinen Zugang zu diesem Inhalt.

Artikel in diesem Heft

https://doi.org/10.1515/hmbci-2021-0017

Schlagwörter für diesen Artikel

disease-free-interval; endometrial carcinoma; endometrioid; PTEN